6,000 heart attack patients enrolled in major registry study
NCT ID NCT07400601
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study is a registry that will follow 6,000 people who had a heart attack and were treated with emergency angioplasty at Zhongshan Hospital. Researchers will collect information on their health, procedures, and medications, and track their recovery for up to two years. The goal is to better understand patient outcomes and improve future treatment for heart attacks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Started
-
Feb 2026
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study is a registry-based cohort investigation, prospectively enrolling patients who were diagnosed with acute myocardial infarction and underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, between January 1, 2009, and December 31, 2028.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Elevated or decreasing levels of cardiac troponin T, with at least one measurement exceeding 0.014 ng/mL; * Presence of at least one of the following: symptoms of myocardial ischemia; newly onset ischemic changes on ECG; pathological Q wave; imaging evidence of new loss of viable myocardium or regional wall motion abnormalities consistent with ischemia; coronary angiography confirming the presence of a thrombus; * Undergoing primary PCI; * Voluntary informed consent to participate in the study. Exclusion Criteria: * Inability to complete emergent PCI (e.g., due to intraoperative complications or inability to tolerate the procedure). * Prior administration of thrombolytic therapy before PCI. * Diagnosis of type 2 or type 3 myocardial infarction.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Zhongshan Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A temporary wire that keeps hearts beating on cue
- AI may spot deadly heart rhythms before they strike
- Antioxidant infusion may shield the heart from reperfusion injury
- Can a temporary heart pump save more lives in cardiogenic shock?
- Can a Community-Based rehab program boost heart recovery after a first attack?
- AI on a simple ECG: a new way to gauge heart attack severity?